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Introduction
Anti-Müllerian hormone (AMH) is produced by granulosa cells 
of small growing ovarian follicles and has been shown to affect 
follicular growth and development as well as production of 
steroid hormones [1-3]. Serum AMH levels reflect the number of 
small growing follicles, and several studies have shown that AMH 
correlates well with antral follicle count assessed via transvaginal 
ultrasound [4]. During recent years, it has become routine 
practice to measure circulating anti-Müllerian hormone (AMH) 
levels to follow the ovarian reserve.
Measurement of AMH levels was facilitated by the development 
of sensitive enzyme-linked immunosorbent assays, ELISAs [5-7], 
where the first commercially available assay had a lower limit of 
detection of 0.1 ng/mL (IOT assay, merchandized by Beckman 
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Abstract
Background: Measurement of anti-Müllerian hormone (AMH) is a valuable 
clinical tool for evaluating ovarian function. The present study aims to evaluate 
the reliability of AMH measurements obtained from samples kept for long-term 
storage with or without intermittent thawing.
Methods and findings: Serum samples from 35 young female cancer patients 
were prospectively collected and stored at -80°C from 2007 until 2010. In 2011, 
AMH was analyzed with the DSL assay. During storage, the samples were exposed 
to a freezer error in 2013 that resulted in their being thawed up to 11°C for a 
maximum of 21 days and then refrozen. In 2014, the same samples (new aliquots) 
were analyzed with the Ansh-AMH assay. To test the reliability of the results from 
2014, we conducted a thawing experiment on serum samples from 10 randomly 
selected females and compared the Ansh-AMH results for samples stored in a 
freezer with aliquots from the same samples that were stored at 11°C for 1, 3, 7, 
14, and 21 days, respectively.
Average AMH levels were 1.6 times higher when assayed with the Ansh-AMH 
compared with the DSL-AMH, which is in line with reported agreement between 
these types of assays. The same difference between the assays was found in 
samples that differed two years in storage time. The Ansh-AMH levels from ten 
serum samples without long-term storage were not influenced by exposure to 
11°C for up to 21 days.
Conclusions: The results indicate that long-term storage at -80°C and episodes of 
thawing have little impact on AMH levels analyzed with current methods. These 
data are reassuring and enable longitudinal studies to be planned that will analyze 
all collected serum samples simultaneously.
Keywords: Anti-Müllerian hormone, Immunoassay, Sample storage, Thawing, 
Freezing
Abbreviations: AMH: Anti-Müllerian Hormone, FSH: Follicle Stimulating Hormone, 
LH: Luteinizing Hormone, ELISA: Enzyme-Linked Immunosorbent Assay
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Coulter) [8]. Subsequently, two more sensitive assays from 
Diagnostic System Lab (DSL) and an improved ELISA assay from 
Beckman Coulter (AMH Gen II, using the same antibodies as 
DSL) were introduced. In 2012 a fourth commercially available 
AMH assay was introduced; the AMH ELISA, AL-105-I, Ansh Labs 
Houston, TX, USA with a lower limit of detection of 0.023 ng/mL.
Due to lack of standard reference material for AMH, the AMH 
assays show a consistent difference in results. The Gen II assay 
gave 22-40% higher results than the DSL assay did in two studies 
[9,10], whereas another study showed 20% lower values for the 
Gen II assay versus the DSL assay [11]. The correlation, however, 
was very good in both assays. These findings questioned the 
robustness of the AMH assays in different settings. Furthermore, 
it has been suggested that AMH assays may exhibit pre-analytical 
variability with probable influence on sample handling in the 
laboratory and perhaps also on long-term stability [12]. Until 
now, few studies have been conducted on the impact of long-
term freezer storage on AMH results [12]. The influence on AMH 
results after intermittent thawing-which is often required in 
long-term studies-has also been discussed, as analytical methods 
improve and change over time [13,14].
Our own experience of a mishap with a freezer led us to conduct 
the current study. The aim of this study was to test the robustness 
of AMH levels in a clinical setting after long-term storage of serum 
samples at -80°C and to investigate the potential influence of a 
period of thawing.
Material and Methods
Serum samples from 35 young female patients (0.3-16.5 years) 
were prospectively collected. All females were diagnosed with 
cancer or hematological disease during 2007-2010 and treated 
at the Department of Pediatric Oncology and Hematology, 
Skåne University Hospital, Sweden. Blood from a central venous 
catheter was collected for both serum and Li-heparin plasma at 
diagnosis and approximately once every three months during, 
and regularly up to three years after cessation of treatment. 
The samples were transported to the laboratory, centrifuged, 
aliquoted and stored at -80°C. The first samples were collected 
in February 2007 and the last in December 2010. Altogether 188 
samples were available, i.e. an average of 5 serum samples from 
each patient.
The 188 serum samples were analyzed for the first time in May 
2011. Samples were assayed with the DSL-10-14400, Diagnostic 
System Laboratories Inc., Webster, TX, USA, (DSL-AMH) according 
to the manufacturer’s instructions. The lower limit of detection 
was 0.04 ng/mL [15].
After storage at -80°C, most of the samples were exposed to 
an accidental period of thawing up to 11°C for a period of up 
to 21 days and then refrozen again in April 2013. The same 188 
serum samples (new aliquots) were again analyzed for AMH in 
May 2014. At that time, as the DSL-AMH method was no longer 
available, the samples were reanalyzed with AMH ELISA, AL-105-I, 
Ansh Labs Houston, TX, USA (Ansh-AMH), also according to the 
manufacturer’s instructions and with a lower limit of detection of 
0.023 ng/mL. Figure 1 shows the flowchart of these events. 
All AMH analyses were performed at the Laboratory of 
Reproductive Biology, Copenhagen, Denmark. Interassay 
coefficients of variation of two independent samples were 4.6% 
and 8.0% (N=8).
Written informed consent was obtained from each patient and/
or her parents prior to inclusion in the study. The study was 
approved by the Regional Ethics Committee, Medical Faculty, 
Lund University, Sweden (approval number 211/2006).
To provide additional data for comparison on long-term stability, 
FSH and LH were analyzed in 215 and 213 paired samples, 
respectively. One aliquot was analyzed in 2011 and the other in 
2014 at the Department of Clinical Chemistry, Skåne University 
Hospital, Lund, Sweden, all with the above thawing episode in 
between. The assays used for FSH and LH (Roche Diagnostics, 
Mannheim, Germany) had a lower limit of detection in both 
assays of 0.1 IU/L. All analyses were performed on thawed 
plasma/serum samples.
A thawing experiment on serum samples from 10 pre- or 
postmenopausal female patients was conducted. All patients had 
detectable AMH values. Six same-sample aliquots per patient 
were placed in a -80°C freezer. Five aliquots from each patient 
were thawed up to 11°C for 1, 3, 7, 14 and 21 days, respectively, 
and then refrozen again prior to analysis with the Ansh-AMH 
assay.
All statistical analyses were performed in STATA version 13, and 
Figure 1 Flowchart of 188 samples from 35 young female cancer 
patients. AMH was analyzed with the DSL and Ansh 
methods in 2011 and 2014, respectively, with a period 
of thawing in between. FSH and LH were analyzed in 
2011 and 2014.
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the figures were created in GraphPad Prism version 5.01. We 
calculated the correlation, agreement, and limits of agreement 
for the AMH values of the 188 serum samples before and after 
the thawing episode, in the thawing experiment, and for the FSH 
and LH measurements [16]. In the analysis of agreement we used 
logarithmic transformation to stabilize variance. We excluded the 
values under the detection level from the analysis of agreement, 
and present those separately. The correlation coefficient was 
calculated using Spearman’s correlation coefficient.
Results
Altogether 188 serum samples were analyzed for AMH at two 
time points, in 2011 and in 2014. The analysis showed that 75 
samples had undetectable AMH values when measured at 
both time points with DSL-AMH and Ansh-AMH, respectively. 
Undetectable values are explained by the toxic effect on the 
ovaries from treatment with chemotherapy and/or radiotherapy. 
Nine serum samples had a value above the detection limit with 
one of the methods but not with the other, which mainly reflects 
the different detection levels of the assays.
In 104 serum samples with detectable AMH levels with both 
methods, the Ansh-AMH analyzed in 2014 showed average 
values 1.6 times higher than the DSL-AMH analysis in 2011 (limits 
of agreement 0.9-3.0) and r=0.96 as shown in Figure 2A. Similar 
results were obtained for the 36 serum samples from 2007-2008 
stored two years longer compared with the 68 serum samples 
stored in 2009-2010 (1.7 times higher, limits of agreement 0.9-
2.9, compared with 1.6 times higher, limits of agreement 0.9-3.0, 
respectively). The correlation coefficient was r=0.97 between the 
Ansh-AMH and the DSL-AMH in the 2007-2008 samples, and 0.96 
in the 2009-2010 samples (Figure 2B and 2C).
For comparison, we studied levels of FSH and LH in 215 and 213 
paired samples, respectively, that were analyzed at the same 
time points, 2011 and 2014, i.e. before and after the freezer error 
with the same analytical methods (Figure 1). We found good 
overall agreement for FSH and LH values between the two time 
points, 0.97 (limits of agreement 0.85 to 1.10) and 0.95 (limits of 
agreement 0.79 to 1.10), with a correlation coefficient of r=0.98 
and 0.94, respectively (Figure 3A and 3B).
In the experiment with serum samples exposed to thawing for 
up to 11°C for 1-21 days, the AMH levels remained unaffected 
(Figure 4). The limits of agreement with the reference sample 
(no thawing) were all close to 1 (between 0.97 and 1.04).
Discussion
Longitudinal clinical laboratory studies may encounter challenges 
such as change of analysis methods and sometimes repeated 
freeze-thaw cycles. A period of thawing for up to 21 days did 
not affect the AMH results in our own experimental study. In our 
longitudinal study we observed negligible effects on AMH levels 
when long-term storage at -80°C was extended for an additional 
two years. A change of AMH assays during the investigation 
period constitutes a special challenge as an international AMH 
standard is lacking.
This study is one of few dealing with AMH reliability after long-
term storage in a freezer. Rey et al. found in a study from 1993 
that AMH values analyzed with an “in-house assay” increased 
by 230% after a few weeks in a -20°C freezer, probably due to 
proteolysis [17]. In 2013, Beckman Coulter reported in a Field 
Safety Notice (FSN-20434-3) that complement factors in serum 
can influence measured levels of AMH due to interference. Later, 
two studies of short-term storage at -20 and  -80°C, respectively, 
showed fair stability with the Gen II AMH assay [18,19]. In 2014, 
Gassner et al showed reliable results with an automated AMH 
assay after long-term storage for up to nine months at -20°C and 
-80°C [14].
In the current study we compared the results from analyses with 
two different AMH methods on serum samples stored at -80°C 
subjected to a period of thawing to 11°C and with an extended 
storage period of two years. A similar conversion factor was 
observed even if the samples were stored two years longer, 
with 1.6-1.7 times higher values using the Ansh-AMH method 
compared with the DSL-AMH method. However, as the limits of 
agreement were wide, we cannot exclude the possibility that an 
extended storage time may result in a minor drift of the AMH 
measurements. The difference between the two AMH methods 
was in agreement with other studies comparing Ansh-AMH 
and GenII-AMH (the latter method using the same antibody 
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Figure 2 Correlation between DSL-AMH measured in 2011 and Ansh-AMH measured in 2014 with different storage time in between. 
(A) All samples with detectable values, n=104/188, r=0.96. (B) Samples collected 2007–2008 with detectable values, n=36/66, 
r=0.97. (C) Samples collected 2009–2010 with detectable values, n=68/122, r=0.96
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as DSL-AMH), which resulted in 1.4-1.8 times higher values 
with Ansh-AMH [20,21]. No previous studies report conversion 
factors between Ansh-AMH and DSL-AMH, and as there is no 
international AMH standard, comparison between the different 
assays is difficult. Our observations of negligible influence on the 
AMH results using either the DSL-AMH or Ansh-AMH method 
after long-term storage at -80°C are in line with those of Fleming 
and co-workers, who reported stable levels of AMH (Gen II) even 
after a storage period of more than three years at -20°C [22].
Regarding long-term storage, freezer temperature might also be 
of importance as it was demonstrated that after storage at -20°C 
for five days, the AMH (Gen II) levels increased 23%, but were 
unchanged after storage at -80°C [11]. The influence of different 
freezing temperatures was not observed in the study by Gassner, 
although the freezing time was extended to up to nine months 
[14]. Whereas this might suggest that recent AMH assays are 
more robust, further studies are needed.
The effect of thawing on the AMH results, especially after 
repeated freeze-thaw cycles, was also recently discussed in the 
review by Rustamov et al. [12]. Few studies have been published 
on this matter, although the publications dealing with AMH levels 
in different clinical settings have increased enormously over the 
past 10-15 years since AMH methods became clinically available. 
In longitudinal studies, it is not unusual to repeat thawing and 
refreezing as analytical methods change and improve over 
time. In one study, Al-Qahtani et al demonstrated unchanged 
immunoreactivity after repeated freeze-thaw cycles at -80°C after 
short-term storage for 4 days with an in-house AMH method [13]. 
In another study [18], Gen II-AMH increased by 15% in serum and 
5% in plasma after three cycles of freeze-thawing. In the study 
by Gassner in 2014, no change in AMH was demonstrated after 
up to three freeze-thaw cycles with an automated assay [14]. 
Our samples were exposed to a thawing period of up to 21 days 
due to a freezer error. Nevertheless, as shown by the current 
experiment with unchanged AMH levels for 10 serum samples 
thawed for up to 21 days, we conclude that the measured AMH 
levels in our longitudinal study were reliable. Thus, an extended 
thawing episode of up to 3 weeks up to 11°C had no impact on 
the Ansh-AMH results in our laboratory.
Sample handling procedures, such as time from collection to 
freezing, should also be considered, as they can differ and might 
influence the AMH results obtained.
Several studies examined AMH stability in unfrozen serum 
samples both at room temperature and in a fridge. In one study, 
there was an average increase of 58% in the Gen II MH levels 
after sample storage at room temperature for 7 days [11] in 
another study, the increase in Gen II AMH levels was 31% after 
storage at 20°C for 90 hours [23]. Kumar et al., [18] used GenII 
AMH analysis to demonstrate that unfrozen serum and plasma 
samples stored at 2°- 8°C for up to 7 days showed a 4% variation 
compared with samples analyzed immediately. It has been 
pointed out that detailed recommendations for AMH sample 
handling, transportation, and storage are needed [11,14]. The 
samples in our study were exposed to room temperature during 
transportation to the local laboratory and after preparation they 
were stored at -80°C within a few hours. This sample handling 
has with current knowledge probably negligible influence on the 
AMH results.
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Figure 3 (A) Correlation between FSH, analyzed in 2011 and 2014 with the same method, n=215, r=0.98. (B) Correlation between LH 
analyzed in 2011 and 2014 with the same method, n=213, r=0.94.
Fre
ez
er
1 d
ay
3 d
ay
s
7 d
ay
s
14
 da
ys
21
 da
ys
0
2
4
6
8
10
An
sh
-A
M
H 
ng
/m
L
Figure 4 AMH levels in 10 female patients from which six aliquots 
per patient were put in the freezer. Five aliquots from 
the same patients were thawed up to 11°C for 1, 3, 7, 14 
and 21 days, respectively, and then refrozen. Ansh-AMH 
showed stable results.
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Conclusion
In conclusion, AMH values are robust with the assays employed in 
the current study, even after long-term storage and a prolonged 
episode of thawing. Whether the storage time is two or four 
years has no significant influence on the results. These data are 
reassuring and enable the planning of longitudinal studies that 
simultaneously analyze AMH for all collected serum samples.
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